Frank Worden
About
Frank Worden is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine and Oncology.
According to data from OpenAlex, Frank Worden has authored 21 papers receiving a total of 817 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Otorhinolaryngology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Frank Worden's work include Head and Neck Cancer Studies (12 papers), Thyroid Cancer Diagnosis and Treatment (4 papers) and Cancer Diagnosis and Treatment (4 papers). Frank Worden is often cited by papers focused on Head and Neck Cancer Studies (12 papers), Thyroid Cancer Diagnosis and Treatment (4 papers) and Cancer Diagnosis and Treatment (4 papers). Frank Worden collaborates with scholars based in United States, Canada and United Kingdom. Frank Worden's co-authors include Teresa Lyden, Douglas B. Chepeha, Avraham Eisbruch, Hyungjin Myra Kim, Felix Y. Feng, Mary Feng, Marc J. Haxer, Mark E. Prince, Carol R. Bradford and Gregory T. Wolf and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.
In The Last Decade
Frank Worden
20 papers receiving 804 citations
Peers
Frank Worden
Mathew J. Schipper United States
H.-J. Thiel Germany
Kie Kian Ang United States
Emanuela Olmetto Italy
Nachi Palaniappan United Kingdom
S. Fondelli Italy
Ch. Popella Germany
R. Barca Italy
Danita Kannarunimit Thailand
Sarah Riley United States
Citations per year, relative to Frank Worden Frank Worden (= 1×)
peers
Mathew J. Schipper
Countries citing papers authored by Frank Worden
Since
Specialization
Citations
This map shows the geographic impact of Frank Worden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Worden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Worden more than expected).
Fields of papers citing papers by Frank Worden
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Frank Worden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Worden. The network helps show where Frank Worden may publish in the future.
Co-authorship network of co-authors of Frank Worden
This figure shows the co-authorship network connecting the top 25 collaborators of Frank Worden. A scholar is included among the top collaborators of Frank Worden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Worden. Frank Worden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Weiss, Jessica, John M. Kaczmar, Kevin J. Harrington, et al.. (2024). 879P VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 35. S628–S628.
2.
Mierzwa, Michelle, Richard P. Medlin, Keith Casper, et al.. (2021). Anticipating Poor Outcomes: A Prognostic Machine Learning Model of Unplanned Visits to the Emergency Department for Patients Undergoing Treatment for Head and Neck Cancer Using Comprehensive Multi-Factor Electronic Health Records. International Journal of Radiation Oncology*Biology*Physics. 111(3). S64–S65.
3.
Brose, Marcia S., Johannes W. A. Smit, C-C. Lin, et al.. (2020). 1918P Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). Annals of Oncology. 31. S1087–S1087.
4.
Anderson, Carryn M., Deborah Saunders, Neal Dunlap, et al.. (2020). Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 106(5). 1221–1222.
5.
Sacco, Alessandra, Rong Chen, Debasis Ghosh, et al.. (2020). An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis. International Journal of Radiation Oncology*Biology*Physics. 106(5). 1121–1122.
6.
Anderson, Carryn M., Deborah Saunders, Neal Dunlap, et al.. (2020). 2-Year Outcomes Of Phase Iib, Randomized, Double-Blind Trial Of GC4419 Versus Placebo To Reduce Severe Oral Mucositis Due To Concurrent Radiotherapy And Cisplatin For Head And Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 108(3). e789–e789.
7.
Hawkins, Peter G., Yan‐Ping Mao, Frank Worden, et al.. (2018). Sparing All Salivary Glands With IMRT for Head and Neck Cancer: Longitudinal Study of Patient-Reported Xerostomia and Head and Neck Quality Of Life. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1388–1389.
8.
Chiosea, Simion I., L. Sylvia, Michael A. Berman, et al.. (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Thyroid Carcinoma. Archives of Pathology & Laboratory Medicine. 141(4). 559–563.
9.
Seiwert, Tanguy Y., Douglas R. Adkins, Frank Worden, et al.. (2014). Activity of Temsirolimus Added to Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head-and-Neck Cancer: Results of the Randomized Phase 2 Maestro-HN Study. International Journal of Radiation Oncology*Biology*Physics. 88(2). 510–510.
10.
Eisbruch, Avraham, Hyungjin Myra Kim, Felix Y. Feng, et al.. (2011). Chemo-IMRT of Oropharyngeal Cancer Aiming to Reduce Dysphagia: Swallowing Organs Late Complication Probabilities and Dosimetric Correlates. International Journal of Radiation Oncology*Biology*Physics. 81(3). e93–e99.
11.
Hadjiiski, Lubomir M., Suresh K. Mukherji, Sachin K. Gujar, et al.. (2010). Treatment Response Assessment of Head and Neck Cancers on CT Using Computerized Volume Analysis. American Journal of Neuroradiology. 31(9). 1744–1751.
12.
Gibson, Michael K., M.S. Kies, Sohyoung Kim, et al.. (2009). Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report. Journal of Clinical Oncology. 27(15_suppl). 6049–6049.
13.
Figlin, Robert A., Elizabeth Brown, Andrew J. Armstrong, et al.. (2008). NCCN Task Force Report: mTOR Inhibition in Solid Tumors. Journal of the National Comprehensive Cancer Network. 6(S5). S–1.
14.
Kies, M.S., Michael K. Gibson, P. Savvides, et al.. (2008). Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis. Journal of Clinical Oncology. 26(15_suppl). 6072–6072.
15.
Olmos, David, R. Molife, Scott H. Okuno, et al.. (2007). Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors.. Molecular Cancer Therapeutics. 6.
16.
Feng, Felix Y., Hyungjin Myra Kim, Teresa Lyden, et al.. (2007). Intensity-Modulated Radiotherapy of Head and Neck Cancer Aiming to Reduce Dysphagia: Early Dose–Effect Relationships for the Swallowing Structures. International Journal of Radiation Oncology*Biology*Physics. 68(5). 1289–1298.
17.
Cohen, Ezra E.W., E. Vokes, M.S. Kies, et al.. (2007). 5507 ORAL A phase 2 study of axitinib (AG-013736; AG) in patients (pts) with advanced thyroid cancers. European Journal of Cancer Supplements. 5(4). 326–326.
18.
Cohen, Ezra E.W., Everett E. Vokes, Lee S. Rosen, et al.. (2007). A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. Journal of Clinical Oncology. 25(18_suppl). 6008–6008.
19.
Fung, Kevin, Teresa Lyden, Jungwha Lee, et al.. (2005). Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. International Journal of Radiation Oncology*Biology*Physics. 63(5). 1395–1399.
20.
Worden, Frank, et al.. (2004). Phase II study of fenretinide in patients with small cell lung cancer (SCLC) with progression after first- or second-line chemotherapy. Journal of Clinical Oncology. 22(14_suppl). 7299–7299.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mathew J. Schipper Breakdown of academic impact, for papers by H.-J. Thiel Breakdown of academic impact, for papers by Kie Kian Ang Breakdown of academic impact, for papers by Emanuela Olmetto Breakdown of academic impact, for papers by Nachi Palaniappan Breakdown of academic impact, for papers by S. Fondelli Breakdown of academic impact, for papers by Ch. Popella Breakdown of academic impact, for papers by R. Barca Breakdown of academic impact, for papers by Danita Kannarunimit Breakdown of academic impact, for papers by Sarah Riley